Semagultide Novo Nordisk Stock

Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, beginning with a 3% decline on Monday from last Friday's close, and falling another 2.

Seeking Alpha · 1d

Novo Nordisk: Dips Like These Come Once Every Few Years

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy with promising growth in obesity care.

Investing.com on MSN · 2d

Bernstein raises Novo Nordisk stock target to DKK620

Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating. The $365 billion market cap company,

The Motley Fool on MSN · 8d

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk ( NVO -3.62%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P 500 ( ^GSPC 1.04%) gained 0.2%, and the Nasdaq Composite ( ^IXIC 1.50%) lost 0.1% on the day.

3don MSN

Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk (NVO) Investors are Alerted of the Pending Class Action and are Urged to Contact BFA Law by March 25 Deadline

New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Yahoo Finance11d

Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

Novo Nordisk NVO is scheduled to report fourth ... demand for NVO’s diabetes and obesity care medicines, especially semaglutide. Notably, semaglutide, a GLP-1 agonist, is approved as an ...

5hon MSN

Why Structure Therapeutics Stock Was Stumbling This Week

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Hims & Hers Stock (HIMS) Falters on Backlash Over Super Bowl Ad

Telehealth company Hims & Hers Health (HIMS) recently stirred up controversy with its ad promoting its compounded weight-loss ...

Novo Nordisk: 2024 Earnings Review

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Morningstar4d

NVO CLASS ACTION: Novo Nordisk 18% Stock Drop Triggers Class Action — Contact BFA Law before March 25 Deadline (NYSE:NVO)

On this news, the price of Novo Nordisk stock declined roughly 18% during the course of the trading day, from a closing price of $103.44 per share on December 19, 2024 to $85.00 per share on ...

FiercePharma1d

'We cannot stay silent': Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results